389 related articles for article (PubMed ID: 17379322)
1. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.
Molden T; Kraus I; Skomedal H; Nordstrøm T; Karlsen F
J Virol Methods; 2007 Jun; 142(1-2):204-12. PubMed ID: 17379322
[TBL] [Abstract][Full Text] [Related]
2. NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses.
Jeantet D; Schwarzmann F; Tromp J; Melchers WJ; van der Wurff AA; Oosterlaken T; Jacobs M; Troesch A
J Clin Virol; 2009 Jul; 45 Suppl 1():S29-37. PubMed ID: 19651366
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of E6/E7 mRNAs of high risk human papilloma virus types by a commercial automatized NASBA assay in cervical swabs].
Ardiç N; Oztürk O; Ergünay K; Sezer O
Mikrobiyol Bul; 2009 Jul; 43(3):463-9. PubMed ID: 19795622
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age.
Molden T; Kraus I; Karlsen F; Skomedal H; Hagmar B
Gynecol Oncol; 2006 Jan; 100(1):95-100. PubMed ID: 16153696
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
[TBL] [Abstract][Full Text] [Related]
6. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay.
Dixon EP; King LM; Adams MD; Grønn P; Murphy PG; Brown CA; Brough GH; Skomedal H; Malinowski DP; Fischer TJ
J Virol Methods; 2008 Dec; 154(1-2):220-2. PubMed ID: 18761379
[TBL] [Abstract][Full Text] [Related]
7. Analytical performance of RNA isolated from BD SurePath™ cervical cytology specimens by the PreTect™ HPV-Proofer assay.
Dixon EP; Grønn P; King LM; Passineau H; Doobay H; Skomedal H; Hariri J; Hay SN; Brown CA; Fischer TJ; Malinowski DP
J Virol Methods; 2012 Nov; 185(2):199-203. PubMed ID: 22820075
[TBL] [Abstract][Full Text] [Related]
8. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay.
Halfon P; Benmoura D; Agostini A; Khiri H; Martineau A; Penaranda G; Blanc B
J Clin Virol; 2010 Feb; 47(2):177-81. PubMed ID: 20022804
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.
Lie AK; Kristensen G
Expert Rev Mol Diagn; 2008 Jul; 8(4):405-15. PubMed ID: 18598223
[TBL] [Abstract][Full Text] [Related]
10. Analytical characterization of the APTIMA HPV Assay.
Dockter J; Schroder A; Eaton B; Wang A; Sikhamsay N; Morales L; Giachetti C
J Clin Virol; 2009 Jul; 45 Suppl 1():S39-47. PubMed ID: 19651368
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
12. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men.
Silling S; Kreuter A; Hellmich M; Swoboda J; Pfister H; Wieland U
J Clin Virol; 2012 Apr; 53(4):325-31. PubMed ID: 22261122
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
Broccolo F; Fusetti L; Rosini S; Caraceni D; Zappacosta R; Ciccocioppo L; Matteoli B; Halfon P; Malnati MS; Ceccherini-Nelli L
J Med Virol; 2013 Mar; 85(3):472-82. PubMed ID: 23280876
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring.
Cuschieri KS; Whitley MJ; Cubie HA
J Med Virol; 2004 May; 73(1):65-70. PubMed ID: 15042650
[TBL] [Abstract][Full Text] [Related]
17. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.
Andersson S; Hansson B; Norman I; Gaberi V; Mints M; Hjerpe A; Karlsen F; Johansson B
Int J Oncol; 2006 Sep; 29(3):705-11. PubMed ID: 16865288
[TBL] [Abstract][Full Text] [Related]
18. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)].
Sotlar K; Diemer D; Stubner A; Menton S; Menton M; Dietz K; Wallwiener D; Bültmann B
Verh Dtsch Ges Pathol; 2005; 89():195-200. PubMed ID: 18035691
[TBL] [Abstract][Full Text] [Related]
19. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
Kraus I; Molden T; Holm R; Lie AK; Karlsen F; Kristensen GB; Skomedal H
J Clin Microbiol; 2006 Apr; 44(4):1310-7. PubMed ID: 16597856
[TBL] [Abstract][Full Text] [Related]
20. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
